Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Total Debt (2016 - 2025)

Historic Total Debt for Cytosorbents (CTSO) over the last 9 years, with Q3 2025 value amounting to $14.6 million.

  • Cytosorbents' Total Debt rose 551.22% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 551.22%. This contributed to the annual value of $14.0 million for FY2024, which is 17754.11% up from last year.
  • Per Cytosorbents' latest filing, its Total Debt stood at $14.6 million for Q3 2025, which was up 551.22% from $14.4 million recorded in Q2 2025.
  • Cytosorbents' 5-year Total Debt high stood at $14.6 million for Q3 2025, and its period low was $4.4 million during Q1 2024.
  • For the 4-year period, Cytosorbents' Total Debt averaged around $9.9 million, with its median value being $13.7 million (2024).
  • Per our database at Business Quant, Cytosorbents' Total Debt skyrocketed by 85.71% in 2023 and then surged by 22034.52% in 2025.
  • Quarter analysis of 4 years shows Cytosorbents' Total Debt stood at $5.0 million in 2022, then rose by 0.86% to $5.0 million in 2023, then skyrocketed by 177.54% to $14.0 million in 2024, then increased by 4.08% to $14.6 million in 2025.
  • Its Total Debt stands at $14.6 million for Q3 2025, versus $14.4 million for Q2 2025 and $14.2 million for Q1 2025.